动物造模,高尿酸血症模型 z-bio 2022-11-02 336

　　Objective: To establish a rat model of hyperuricemia and investigate whether hyperuricemia can cause secondary cardiovascular diseases.

　　Methods: Thirty two SPF male SD rats were randomly divided into normal control group (Group C), potassium oxazinate model group (Group M1), potassium oxazinate combined with high sugar and high fat diet model group (Group M2), and potassium oxazinate combined with yeast extract diet model group (Group M3). There were 8 rats in each group, and the model was established continuously for 3 weeks. The hyperuricemia model of rats was studied by comparing the serum uric acid (UA), blood urea nitrogen (BUN), creatinine (Cr), insulin (INS), blood glucose (GLU), triglyceride (TG) and other indicators of rats, as well as the results of pathological examination.

　　Results: The hyperuricemia model rats reproduced by gavage of 750 mg/kg body weight potassium oxazinate combined with yeast extract feed had the characteristics of significantly increased UA level (P<0.01), long maintenance time, and renal pathological changes in 3/8 rats. The hyperuricemia was accompanied by changes in GLU, INS and TG levels and heart pathological changes in 3/8 rats, indicating the occurrence of secondary cardiovascular diseases.

　　Conclusion: The method of potassium oxazinate gavage combined with yeast extract is more suitable for the establishment of long-term hyperuricemia model in rats than that of pure potassium oxazinate, which is accompanied by the occurrence of secondary blood glucose disorder. Therefore, the model establishment scheme can be used for the animal model of the study on the mutual intervention mechanism between hyperuricemia and cardiovascular disease, and further applied to the comprehensive evaluation of the preclinical pharmacodynamics of the therapeutic drugs for hyperuricemia.